Grapefruit juice interaction with oral budesonide: Equal effect on immediate-release and delayed-release formulations

Pharmazie

Volumn 64, Issue 7, 2009, Pages 461-465

  Seidegård, Janeric ^a   Randvall, G ^a   Nyberg, L ^a   Borga O ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CYTOCHROME P450 3A; DEUTERIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASCENDING COLON; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; ILEUM; INTESTINE MUCOSA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; BEVERAGE; CONTROLLED CLINICAL TRIAL; GRAPEFRUIT; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; MICROCAPSULE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BEVERAGES; BUDESONIDE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS PARADISI; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; YOUNG ADULT;

EID: 70349229759     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9554     Document Type: Article

References (21)

1. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD (1995) Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 40: 135-140.
2. Ducharme MP, Warbasse LH, Edwards DJ (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57: 485-491.
3. Edsbäcker S, Andersson T (2004) Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 43: 803-821.
4. Edsbäcker S, Bengtsson B, Larsson P, Lundin P, Nilsson Å , Ulmius J, Wollmer P (2003) A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 17: 525-536.
5. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA (2003) Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74: 121-129.
6. Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39: 289-296.
7. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52: 453-457.
8. Jönsson G, Å ström A, Andersson P (1995) Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 23: 137-142.
9. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB (1994) CYP3A gene expression in human gut ephitelium. Pharmacogenetics 4: 247-259.
10. Kronkvist K, Gustavsson M, Wendel AK, Jaegfeldt H (1998) Automated sample preparation for the determination of budesonide in plasma samples by liquid chromatography and tandem mass spectrometry. J Chromatogr A 823: 401-409.
11. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58: 20-28.
12. Lilja JJ, Kivistö KT, Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastin. Clin Pharmacol Ther 68: 384-390.
13. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99: 2545-2553.
14. McKinnon RA, McManus ME (1996) Localization of cytochromes P450 in human tissues: implications for chemical toxicity. Pathology 28: 148-155.
15. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283: 1552-1562.
16. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Disp 25: 1228-1233.
17. Seidegård J, Nyberg L, Borgå O (2008) Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur J Pharm Sci 35: 264-270.
18. Thörn M, Finnström N, Lundgren S, Rane A, Lööf L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60: 54-60.
19. Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, KijekP, Staubach P, Langguth P (2008) Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res 25: 1591-1600.
20. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE (2003) Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 43: 831-839.
21. Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27: 804-809.